-
Double anti-drugs are in the air! Xencor and Atreca collaborated to develop CD3/tumor new antigen bispecific antibodies, the medical mammoth.
Time of Update: 2020-07-17
July 11, 2020 / emedclub news / - - recently, xencor and atreca reached an agreement to jointly discover, develop and commercialize t-cell-bound bispecific antibodies as a potential treatment for cancer.
-
Video Abstract Paper / NUDT21 inhibits the onset of breast cancer by regulating the expression of CPSF6.
Time of Update: 2020-07-17
results: immunohistochemistry (IHC) analysis showed that the expression of nudt21 in breast cancer was significantly lower than that in benign breast disease tissues.
similarly, the overexpression of nudt21 inhibited cell proliferation, migration, invasion and EMT.
-
The efficacy of imartinib treatment of glioblastoma was not obvious.
Time of Update: 2020-07-17
There is still a lack of special treatment for glioblastoma (GBM) studies have found that GBM over-expression of a variety of tyrosine kinase receptors is considered to be an important target for ta
-
Immunotherapy re-introduced metastatic renal cell carcinoma, with an efficiency of 23%!
Time of Update: 2020-07-17
In the past five years, several immune checkpoint inhibitors (ICI) have been approved for the treatment of metastatic renal cell carcinoma (mRCC), including navulizumab alone or in combination with epilimumab, pabolizumab + acitinib, avelumab + acitinib.
-
Whether the genetic risk is high or low, doing these points can reduce the risk of breast cancer.
Time of Update: 2020-07-17
source: to assess whether a healthy lifestyle can reduce the risk of breast cancer in people with different genetic risks, researchers from the University of Manchester in the UK Pixabay analyzed data from UK Biobank, the largest human genetic cohort sample bank in the world, involving more than 90 thousand female subjects over the age of 40.
-
Self Renew column, F-627 of Efan Medicine.
Time of Update: 2020-07-17
according to the small edition, combined with the differentiation of f-627 and the average market share of biological similar drugs in the United States, the peak foreign sales of f-627 can be conservatively estimated at 1 / 10 of the peak sales of neulasta (about 4.7 billion US dollars), that is, about 500 million US dollars.
-
Transformil-18 enhances cancer immunotherapy.
Time of Update: 2020-07-17
Cytokine is a secreted protein that can be used in immunotherapy for tumors but because the specificity of its treatment is not ideal, and may be toxic, so clinical application is limited IL-18 is a
-
Nature Sub-Journal: Drug screening combined with CRISPR technology to improve the efficacy of anti-cancer drugs.
Time of Update: 2020-07-17
this further understanding of the biological mechanisms supporting drug response will help us develop new cancer drugs more quickly and effectively, and bring us closer to the precise treatment of cancer patients.
-
CD20xCD3 bispecific antibodies! Rochemosuuzumab is qualified by FDA for breakthrough drug treatment for follicular lymphoma (FL)
Time of Update: 2020-07-17
!--webeditor:page title"--July 14, 2020 /PRNewswire/ -- Roche has announced that the U.S Food and Drug Administration (FDA) has granted the Mosunetuzumab Breakthrough Drug (BTD), a T-cell-combined CD2
-
2020 BOC/BOA. Annual progress in liver and bile pancreas research.
Time of Update: 2020-07-17
phase II apact study albumin paclitaxel combined with gemcitabine compared with gemcitabine monotherapy in adjuvant treatment of pancreatic cancer: prognosis in different regions.
-
230,000 studies confirmed the risk of serrated polyps raising the risk of colon cancer, and Professor Huang Xiaojun led the JCO article. Tumor intelligence.
Time of Update: 2020-07-17
Jto: guidelines for diagnosis and management of patients with pulmonary neuroendocrine tumors Chinese Journal of oncology: consensus of clinicopathologists on detection of PD-L1 expression in non-small cell lung cancer in China The journal updated the perspectives column online to report the results of a large retrospective study published on July 7 in gastroenterology, providing more accurate information on the relationship between serrated polyps (SP) and the risk of colon cancer.
-
Chinese scientists have revealed for the first time a panoramic view of the molecules of lung adenocarcinoma.
Time of Update: 2020-07-17
Lung cancer is the highest incidence rate and mortality rate in China and even worldwide. in China, there are more than 700000 lung cancer cases and more than 600000 deaths every year in China. lung a
-
Australian scientists have developed new blood tests to help treat invasive prostate cancer.
Time of Update: 2020-07-17
the study was led by Dr. Arun Azad, Department of oncology, Peter McCullen cancer center and published in the European Journal of Urology entitled "combined cell free DNA and RNA profiling of the androgen receptor: clinical utility of a new multianalysis liquid biology assay for metastatic prostate In Australia, nearly 20000 men are diagnosed with prostate cancer each year, accounting for a quarter of all male cancer diagnoses.
-
Sci TransMed: New combination therapy or "cold" tumors that are expected to treat non-responsive conventional therapies.
Time of Update: 2020-07-17
July 13, 2020 // In a recent study published in the international journal Science Translational Medicine, scientists from the Sanford Burnham Prebys Institute for Medical Discovery and others have rev
-
The Guide to the Diagnosis and Treatment of Multiple Myeloma in China (Revised 2020) interprets the summary of public welfare project activities online.
Time of Update: 2020-07-17
"Guidelines for diagnosis and treatment of multiple myeloma in China (revised in 2020)" jointly sponsored by hematologists branch of Chinese Medical Doctor Association, multiple myeloma Professional Committee of Chinese Medical Doctor Association and China primary health care foundation ”The public welfare project, four sessions of online interpretation meeting, have been successfully concluded.
-
Summary: Risk factors for hepatocellular carcinoma.
Time of Update: 2020-07-17
is noteworthy that the incidence rate of HCC depends not only on race / ethnicity, gender, age, geographic / demographic factors, but also on several risk factors, such as cirrhosis, hepatitis B virus (HBV) infection, hepatitis C virus (HCV) infection, excessive drinking, non-alcoholic fatty liver disease (NAFLD), obesity, diabetes, metabolic syndrome and environmental toxicity.
-
Anti-Trop-2 ADC drug Trodelvy combined with PD-L1 monoantitic Tecentriq: Treatment of urethral derilopathy and non-small cell lung cancer.
Time of Update: 2020-07-17
The !---- leading biopharmaceutical company in the field of antibody drug coupling (ADC) has announced a partnership with Roche to assess the potential of Thetreves, Immunomedic's anti-Trop-2 ADC drug
-
Ring RNA circTUBGCP3 is expressed in osteosarcoma and promotes the proliferation, migration and viability of osteosarcoma cells through sponge mir-30b.
Time of Update: 2020-07-17
Objective: To investigate the effect of cyclic RNA circtubgcp3 on the proliferation, migration and survival of osteosarcoma cells It is closely related to the various stages of tumorigenesis.
-
Adv Sci . . . The collaboration between He Qingyu/Li Bin/Xu Wei reveals the important role of TGF beta 2 in esophageal cancer metastasis and the strategy of targeted intervention.
Time of Update: 2020-07-17
recently, Professor He Qingyu, researcher Li Bin and associate researcher Xu Wenwen, Key Laboratory of tumor molecular biology, Ministry of education of Jinan University, published the title "direct targeting of CREB1 with imperatorin inhibitors TGF β 2-erk signaling to suppress esophageal cancer" In this paper, we analyzed the expression of TGF β 2 in clinical samples based on public database and clinicopathological data.
-
"Optimized Edition" Herceptin! FC optimized immune-enhanced antibody margetuximab treatment of stomach cancer is strong, and then Ding medicine was introduced into China for development!
Time of Update: 2020-07-17
!--webeditor: "page title" - - July 11, 2020 /PRNewswire/ -- Reding Pharmaceutical Partners MacroGenics recently announced the evaluation of HER2 target antibody margetuximab in conjunction with Merca
